Universal $4 Bn Biosimulation Market | Rhenovia Pharma Ltd., Dassault Systemes SA, Chemical Computing Group, Advanced Chemistry Development, Certara USA, Simulation Plus, Schrodinger, Entelos, Physiomics PLC and Genedata AG

A Research Study Titled, “Biosimulation Market by Product, Application, and End User - Global Industry Analysis and Forecast to 2025” published by Crystal Market Research, states that the biosimulation market is projected to be around $4 billion by 2025.

Biosimulation is one such promising notion to drug discovery and development. It has been developed in order to avoid the hurdles in discovery and development of a new drug by traditional processes. It promises tremendous benefits saving both money and time and improves the predictability in early stage of the drug development. In biosimulation, the relationships between different biological elements are represented using differential equations utilizing simulation techniques to predict the behavior of the biological system and status of biological elements over time.

To request a sample copy or view summary of this report, click the link below: https://www.crystalmarketresearch.com/report-sample/HC0637 .

Competitive Analysis:

Some of the major players in biosimulation market include Rhenovia Pharma Ltd., Dassault Systemes SA, Chemical Computing Group, Inc., Advanced Chemistry Development, Inc., Certara USA, Inc., Simulation Plus, Inc., Schrodinger, Inc., Entelos, Inc., Physiomics PLC, and Genedata AG. The major strategies adopted by them to sustain the market competition are increasing collaborations and partnerships, patient medication, mergers and acquisitions, drug repositioning, modeling and simulations in pediatrics drug development and new product launches. For instance, in December 2016, Chemical Computing Group, Inc. launched new version of its protein structure database system - PSILO 2016.10 with easy access to protein structural information leading to quick discovery of drugs.

Industry Trend Analysis:

The biosimulation market is expected to be around $4 billion by 2025. This growth can be attributed to number of factors such as rise in incidence of chronic diseases such as diabetes, rise in aging population, high rate of drug resistance and failure. Moreover, unavailability of drugs to treat diseases such as AIDS and cancer is expected to further drive the global market. Further, rise in disposable income of the people and technological advancements such as use of micro assays for gene sequencing and analysis is set to contribute to the market growth. However, lack of standard method for biosimulation, lack of knowledge and unavailability of skilled professionals will restraint the market growth.

Product Outlook and Trend Analysis:

Software segment accounted for the largest share of the global biosimulation market in 2016, as software being crucial component of the process. The onset of high end in silico software is expected to open up new pathway for improved personalized medicines and enable better disease care management through improved drug designing and medication.

Application Outlook and Trend Analysis:

Drug development segment accounted for the largest share of the overall market in 2016 and is projected to witness robust growth during the forecast period, due to advancements in software for new drug development. The inclusion of high end software’s in drug designing will facilitate enhanced disease care through development of novel drugs especially in the field of personalized medicine.

End User Outlook and Trend Analysis:

Pharmaceutical and biotechnology companies segment occupied major share of the global market in 2016 owing to rise in adoption rate of high end in silico software’s for developing new and advanced drugs for various diseases such as cancer and diabetes.

Biosimulation market is segmented as follows:

Biosimulation Market, By Product:

Services
In-house Services
Contract Services
Software

Biosimulation Market, By Application:

Drug Discovery
Drug Development
Others

Biosimulation Market, By End User:

Regulatory Authorities
Pharmaceutical & Biotechnology Companies
Academic Research Institutions
CROs

Get More Information of This Report: https://www.crystalmarketresearch.com/report/biosimulation-market .

Market Opportunities:

There is a continuous rise in the demand for advanced software programs, which will provide ample growth opportunities for players operating in the global market. Technological advancements such as gene analysis, sequencing and coding, development of advanced mathematical model for biological assays and new methods of cell-based assays are expected to provide profitable market growth in coming years.

Biosimulation Market, By Region:

North America - U.S, Canada, Mexico

Europe - Germany, France, UK, Italy, Spain, Rest of Europe

Asia-Pacific - Japan, China, Australia, India, South Korea, Rest of Asia Pacific

Rest of the World - Brazil, South Africa, Saudi Arabia, United Arab Emirates, Others

Regional Outlook and Trend Analysis:

North America dominated the global market in 2016. This can be attributed to number of factors such as developed healthcare infrastructure, technological innovations such as development of biochips and advanced cell assay methods, and increase in number of patent files for many drugs and search for new drug entity. Asia-Pacific market is expected to grow at highest rate over the forecast period, owing to various factors such as increase disposable income of people, rapid healthcare infrastructure development and increasing need for integrating IT software in healthcare systems.

Biosimulation Market, List of Tables:

Table 1.Global Biosimulation Market, By Product, 2016-2025 ($Million)
Table 2.Services Market, By Type, 2016-2025 ($Million)
Table 3.Services Market, By Region, 2016-2025 ($Million)
Table 4.In-house Services Market, By Region, 2016-2025 ($Million)
...

Biosimulation Market, List of Figures:

Figure 1.Global Biosimulation Market Share, By Product, 2016 & 2025
Figure 2.Global Biosimulation Market, By Application, 2016 ($Million)
Figure 3.Global Biosimulation Market, By End User, 2016 ($Million)
...

Discuss Our Expert Team: https://www.crystalmarketresearch.com/check-discount/HC0637 .

Key Findings of the Research Study:

• The biosimulation market will be majorly driven by rise in chronic disease incidence such as cancer and diabetes, increasing prevalence of geriatric population, high drug resistance by certain disease related pathogens and high drug failure rate.

• The services segment will exhibit favorable growth over the forecast period as more and more pharmaceutical companies are beginning to outsource their biosimulation processes in order to reduce costs and focus on core competencies.

• North America held a major share of the biosimulation market in 2016, commanding over more than half of the market. Due to presence of highly skilled professionals and research infrastructure along with presence of regulatory authorities ensuring patient safety, this market will show promising growth over the forecast period.

• Asia-Pacific market will exhibit the fastest growth rate during the forecast period due to rapidly improving healthcare infrastructure and growing Healthcare IT expenditure.

TO BE CONTINUED…

About Crystal Market Research:

Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customised research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.

Contact Us:
Judy
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: sales@crystalmarketresearch.com

This release was published on openPR.